A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Chronic Kidney Disease
In brief
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).
Key facts
- Study ID
- NCT07024823
- Run by
- AstraZeneca
- People needed
- 124
- Starts
- 2025-06-09
- Expected to finish
- 2026-12-25
- Last updated by the study team
- 2026-07-01
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Glendale, California, United States (enrolling)
- Research Site — Chicago, Illinois, United States (enrolling)
- Research Site — Saint Paul, Minnesota, United States (enrolling)
- Research Site — San Antonio, Texas, United States (enrolling)
- Research Site — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.